Uniform Data Set version 4
UDSv4 - Template

United States

Reference ID

USDv4

Producer(s)

National Alzheimer’s Coordinating Center (NACC) and the NIA-funded ADRC network

Collections

Clinical Trial

Metadata

DDI/XML JSON

Created on

Jul 02, 2026

Last modified

Jul 07, 2026

Page views

11409

Variable Groups

Variable group: D1b Etiological Diagnosis and Biomarker Support

Variables 120

alzdis

12. Alzheimer's disease

alzdisif

12a. Alzheimer's disease (Primary, contributing, or non-contributing)

amylpet

6a1. Elevated amyloid

autdommut

11. Is there an autosomal dominant pathogenic variant to support an etiological diagnosis? {loc_autdommut_lastvis}

biomad1

8a. Consistent with AD

biomad2

9a. Consistent with AD

biomad3

10a. Consistent with AD

biomarkdx

1. Were any biomarker results used to support the current etiological diagnosis? (Consider any biomarker results from any time that may be clinically relevant)

biomftld1

8b. Consistent with FTLD

biomftld2

9b. Consistent with FTLD

biomftld3

10b. Consistent with FTLD

biomlbd1

8c. Consistent with LBD

biomlbd2

9c. Consistent with LBD

biomlbd3

10c. Consistent with LBD

biomoth1

8d. Consistent with other etiology

biomoth2

9d. Consistent with other etiology

biomoth3

10d. Consistent with other etiology

biomothx1

8d1. Consistent with other etiology (SPECIFY)

biomothx2

9d1. Consistent with other etiology (SPECIFY):

biomothx3

10d1. Consistent with other etiology (SPECIFY):

bloodad

3a. Consistent with AD

bloodftld

3b. Consistent with FTLD

bloodlbd

3c. Consistent with LBD

bloodoth

3d. Consistent with other etiology (SPECIFY): {bloodothx}

bloodothx

3d1. Consistent with other etiology (SPECIFY):

caa

21. Cerebral amyloid angiopathy

caaif

21a. Cerebral amyloid angiopathy (Primary, contributing, or non-contributing)

cort

14b. Corticobasal degeneration (CBD)

cortif

14b1. Corticobasal degeneration (CBD) (Primary, contributing, or non-contributing)

csfad

4a. Consistent with AD

csfftld

4b. Consistent with FTLD

csflbd

4c. Consistent with LBD

csfoth

4d. Consistent with other etiology (SPECIFY): {csfothx}

csfothx

4d1. Consistent with other etiology (SPECIFY):

cte

17. Chronic traumatic encephalopathy

ctecert

17b. If CTE is present, specify certainty:

cteif

17a. Chronic traumatic encephalopathy (Primary, contributing, or non-contributing)

cvd

15. Vascular brain injury (based on clinical and imaging evidence according to your Center's standards)

cvdif

15a. Vascular brain injury (Primary, contributing, or non-contributing)

datscandx

6c. Dopamine Transporter (DAT) Scan - Was DAT Scan data or information used to support an etiological diagnosis?

downs

18. Down syndrome

downsif

18a. Down syndrome (Primary, contributing, or non-contributing)

fdgad

6b1. Consistent with AD

fdgftld

6b2. Consistent with FTLD

fdglbd

6b3. FDG PET - Consistent with LBD

fdgoth

6b4. Consistent with other etiology (SPECIFY):{fdgothx}

fdgothx

6b4a. FDG PET - Consistent with other etiology (specify)

fdgpetdx

6b. FDG PET - Was FDG PET data or information used to support an etiological diagnosis?

fluidbiom

2. Fluid Biomarkers - Were fluid biomarkers used for assessing the etiological diagnosis?

frmdated1b

0a. D1b Biomarker and Etiological Diagnosis - Form date

ftld

14. Frontotemporal lobar degeneration (FTLD)

ftldmo

14c. FTLD with motor neuron disease

ftldmoif

14c1. FTLD with motor neuron disease (Primary, contributing, or non-contributing)

ftldnoif

14d1. FTLD not otherwise specified (NOS) (Primary, contributing, or non-contributing)

ftldnos

14d. FTLD not otherwise specified (NOS)

ftldsubt

14c. FTLD subtype

ftldsubx

14c1. Other FTLD subtype (specify)

hunt

19. Huntington's disease

huntif

19a. Huntington's disease (Primary, contributing, or non-contributing)

imagingdx

5. Imaging - Was imaging used for assessing etiological diagnosis?

imaglac

7a3b. Lacunar infarct(s)

imaglinf

7a3a. Large vessel infarct(s)

imagmach

7a3c. Macrohemorrhage(s)

imagmich

7a3d. Microhemorrhage(s)

imagwmh

7a3e. White matter hyperintensity

imagwmhsev

7a3e1. White-matter hyperintensity severity

initialsd1b

0b. D1b Biomarker and Etiological Diagnosis - Examiner's initials

langd1b

0c. D1b Biomarker and Etiological Diagnosis - Language

late

22. LATE: Limbic-predominant age-related TDP-43 encephalopathy

lateif

22a. LATE (Primary, contributing, or non-contributing)

lbdif

13a. Lewy body disease (Primary, contributing, or non-contributing)

lbdis

13. Lewy body disease

loc_alzdisif

alzdisif primary?

loc_caaif

loc_cortif

cortif primary?

loc_cteif

loc_cvdif

loc_d1b_diagall

Sum of D1b Diagnoses 12-23 marked as primary

loc_d1b_diagset1

Sum of D1b Diagnoses 12-13 marked as primary

loc_d1b_diagset2

Sum of D1b Diagnoses 14 marked as primary

loc_d1b_diagset3

Sum of D1a Diagnoses 15-17 marked as primary

loc_d1b_diagset4

Sum of D1b Diagnoses 18-23 marked as primary

loc_downsif

downsif primary?

loc_ftldmoif

ftldmoif primary?

loc_ftldnoif

ftldnoif primary?

loc_huntif

huntif primary?

loc_lateif

lateif primary?

loc_lbdif

loc_msaif

loc_othcogif

othcogif primary?

loc_prionif

prionif primary?

loc_pspif

msa

16. Multiple system atrophy

msaif

16a. Multiple system atrophy (Primary, contributing, or non-contributing)

othbiom1

8. Other biomarker modality - Was another biomarker modality used to support an etiological diagnosis?

othbiom2

9. Other biomarker modality - Was another biomarker modality used to support an etiological diagnosis?

othbiom3

10. Other biomarker modality - Was another biomarker modality used to support an etiological diagnosis?

othbiomx1

8a1. Other biomarker modality - Was another biomarker modality used to support an etiological diagnosis? (specify)

othbiomx2

9a1. Was another biomarker modality used to support an etiological diagnosis? (SPECIFY):

othbiomx3

10a1. Was another biomarker modality used to support an etiological diagnosis? (SPECIFY):

othcog

23. Other Etiological diagnosis

othcogif

23a. Other Etiological diagnosis (Primary, contributing, or non-contributing)

othcogx

23b. Other Etiological diagnosis - specify

petdx

6a. Tracer-based PET - Were tracer-based PET measures used in assessing an etiological diagnosis?

prion

20. Prion disease (CJD, other)

prionif

20a. Prion disease (CJD, other) (Primary, contributing, or non-contributing)

psp

14a. Primary supranuclear palsy (PSP)

pspif

14a1. Primary supranuclear palsy (PSP) (Primary, contributing, or non-contributing)

structad

7a1. Atrophy pattern conistent with AD

structcvd

7a3. Consistent with cerebrovascular disease (CVD)

structdx

7a. Structural Imaging (i.e., MRI or CT) - Was structural imaging data or information used to support an etiological diagnosis?

structftld

7a2. Atrophy pattern consistent with FTLD

taupet

6a2. Elevated tau pathology

tracerad

6d1. Consistent with AD

tracerftld

6d2. Consistent with FTLD

tracerlbd

6d3. Consistent with LBD

traceroth

6d4. Consistent with other etiology (SPECIFY):

tracerothx

6d4a. Consistent with other etiology (specify)

tracothdx

6d. Other tracer-based imaging - Were other tracer-based imaging used to support an etiological diagnosis? (SPECIFY): {tracothdxx}

tracothdxx

6d1a. Were other tracer-based imaging used to support an etiological diagnosis? (specify)

Back to Catalog